United Therapeutics Corporation Cash and Cash Equivalents, Period Increase (Decrease)
United Therapeutics Corporation (UTHR) reported Cash and Cash Equivalents, Period Increase (Decrease) of $121.40 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-01
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $121.40M, a 46.66% decline year-over-year.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $13.20M.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$89.90M, a 245.94% decline year-over-year.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$186.80M.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$35.90M.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$317.90M, a 266.27% decline from fiscal 2016.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for fiscal 2016 was $191.20M, a 55.95% decline from fiscal 2015.
- United Therapeutics Corporation cash and cash equivalents, period increase (decrease) for fiscal 2015 was $434.10M, a 282.80% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | $121.40M 10-Q · filed 2019-05-01 | $134.60M derived: sum of 2 quarters · filed 2019-05-01 | $44.70M derived: sum of 3 quarters · filed 2019-05-01 | -$142.10M derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2018-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$76.70M derived: sum of 2 quarters · filed 2019-02-27 | -$263.50M derived: sum of 3 quarters · filed 2019-02-27 | -$35.90M 10-K · filed 2019-02-27 | ||||
| 2018-09-30 | -$89.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$276.70M derived: sum of 2 quarters · filed 2018-10-31 | -$49.10M 10-Q · filed 2018-10-31 | -$411.50M derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2018-06-30 | -$186.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $40.80M 10-Q · filed 2018-08-01 | -$321.60M derived: sum of 3 quarters · filed 2019-05-01 | -$260.00M derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2018-03-31 | $227.60M 10-Q · filed 2019-05-01 | -$134.80M derived: sum of 2 quarters · filed 2019-05-01 | -$73.20M derived: sum of 3 quarters · filed 2019-05-01 | -$189.90M derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2017-12-31 | -$362.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$300.80M derived: sum of 2 quarters · filed 2019-02-27 | -$417.50M derived: sum of 3 quarters · filed 2019-02-27 | -$317.90M 10-K · filed 2019-02-27 | ||||
| 2017-09-30 | $61.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$55.10M derived: sum of 2 quarters · filed 2018-10-31 | $44.50M 10-Q · filed 2018-10-31 | $114.50M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | -$116.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$17.10M 10-Q · filed 2018-08-01 | $52.90M derived: sum of 3 quarters · filed 2019-02-27 | $168.40M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $99.60M 10-Q · filed 2018-05-02 | $169.60M derived: sum of 2 quarters · filed 2019-02-27 | $285.10M derived: sum of 3 quarters · filed 2019-02-27 | $275.80M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $185.50M derived: sum of 2 quarters · filed 2019-02-27 | $176.20M derived: sum of 3 quarters · filed 2019-02-27 | $191.20M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $115.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $106.20M derived: sum of 2 quarters · filed 2017-10-25 | $121.20M 10-Q · filed 2017-10-25 | $187.80M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | -$9.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $5.70M 10-Q · filed 2017-07-27 | $72.30M derived: sum of 3 quarters · filed 2018-02-21 | $583.10M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $15.00M 10-Q · filed 2017-04-26 | $81.60M derived: sum of 2 quarters · filed 2018-02-21 | $592.40M derived: sum of 3 quarters · filed 2018-02-21 | $420.30M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $66.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $577.40M derived: sum of 2 quarters · filed 2018-02-21 | $405.30M derived: sum of 3 quarters · filed 2018-02-21 | $434.10M 10-K · filed 2018-02-21 | $434.10M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $510.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $338.70M derived: sum of 2 quarters · filed 2016-10-27 | $367.50M 10-Q · filed 2016-10-27 | $367.51M 10-Q · filed 2015-10-27 | $267.87M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | -$172.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$143.30M 10-Q · filed 2016-07-28 | -$143.34M 10-Q · filed 2015-07-28 | -$242.93M derived: sum of 3 quarters · filed 2017-02-22 | -$10.06M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $28.80M 10-Q · filed 2016-04-28 | $28.81M 10-Q · filed 2015-04-28 | -$70.83M derived: sum of 2 quarters · filed 2017-02-22 | $162.04M derived: sum of 3 quarters · filed 2017-02-22 | $7.29M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | -$99.63M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $133.24M derived: sum of 2 quarters · filed 2017-02-22 | -$21.50M derived: sum of 3 quarters · filed 2017-02-22 | $113.40M 10-K · filed 2017-02-22 | $113.44M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $232.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $78.13M derived: sum of 2 quarters · filed 2015-10-27 | $213.03M 10-Q · filed 2015-10-27 | $169.69M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | -$154.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | -$19.84M 10-Q · filed 2015-07-28 | -$63.18M derived: sum of 3 quarters · filed 2016-02-25 | -$84.50M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $134.91M 10-Q · filed 2015-04-28 | $91.56M derived: sum of 2 quarters · filed 2016-02-25 | $70.24M derived: sum of 3 quarters · filed 2016-02-25 | $151.67M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | -$43.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$64.66M derived: sum of 2 quarters · filed 2016-02-25 | $16.76M derived: sum of 3 quarters · filed 2016-02-25 | $124.86M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | -$21.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $60.10M derived: sum of 2 quarters · filed 2014-10-28 | $168.20M 10-Q · filed 2014-10-28 | $58.80M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $81.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $189.52M 10-Q · filed 2014-07-29 | $80.13M derived: sum of 3 quarters · filed 2015-02-24 | $186.54M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $108.10M 10-Q · filed 2014-04-29 | -$1.30M derived: sum of 2 quarters · filed 2015-02-24 | $105.11M derived: sum of 3 quarters · filed 2015-02-24 | $105.46M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | -$109.39M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$2.98M derived: sum of 2 quarters · filed 2015-02-24 | -$2.64M derived: sum of 3 quarters · filed 2015-02-24 | -$8.65M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $106.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $106.76M derived: sum of 2 quarters · filed 2013-10-29 | $100.75M 10-Q · filed 2013-10-29 | -$80.56M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$5.66M 10-Q · filed 2013-07-25 | -$186.97M derived: sum of 3 quarters · filed 2014-02-25 | -$164.11M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | -$6.01M 10-Q · filed 2013-04-25 | -$187.32M derived: sum of 2 quarters · filed 2014-02-25 | -$164.46M derived: sum of 3 quarters · filed 2014-02-25 | -$132.30M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | -$181.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$158.44M derived: sum of 2 quarters · filed 2014-02-25 | -$126.29M derived: sum of 3 quarters · filed 2014-02-25 | -$89.49M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $22.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $55.02M derived: sum of 2 quarters · filed 2012-11-01 | $91.82M 10-Q · filed 2012-11-01 | $133.80M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $32.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $68.96M 10-Q · filed 2012-07-26 | $110.94M derived: sum of 3 quarters · filed 2013-02-26 | $35.71M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $36.80M 10-Q · filed 2012-04-26 | $78.78M derived: sum of 2 quarters · filed 2013-02-26 | $3.55M derived: sum of 3 quarters · filed 2013-02-26 | $99.01M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $41.98M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$33.25M derived: sum of 2 quarters · filed 2013-02-26 | $62.21M derived: sum of 3 quarters · filed 2013-02-26 | $151.81M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | -$75.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $20.23M derived: sum of 2 quarters · filed 2011-10-27 | $109.83M 10-Q · filed 2011-10-27 | $75.68M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | $95.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $185.06M 10-Q · filed 2011-07-28 | $150.91M derived: sum of 3 quarters · filed 2012-02-28 | $151.88M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $89.60M 10-Q · filed 2011-04-28 | $55.45M derived: sum of 2 quarters · filed 2012-02-28 | $56.43M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | -$34.15M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$33.17M derived: sum of 2 quarters · filed 2012-02-28 | -$29.10M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $978.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $5.05M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $4.07M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | -$9.87M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |